Business Description
Camp4 Therapeutics is a clinical-stage company focused on developing RNA-based treatments for inherited genetic diseases. Its lead drug, CMP-001, is currently being tested in an early-stage clinical trial for urea cycle disorders, while a second treatment, CMP-002, targets SYNGAP1-related conditions. Founded in 2015 and based in Cambridge, Massachusetts, the company was previously called Marauder Therapeutics before rebranding in 2018.
